glp 1 gip receptor agonist GLP-1 and receptors signal through distinct β-arrestin 2-dependent pathways to regulate pancreatic β cell function Possible mechanisms of action of
Description
doi: 10.1016/j.amjmed.2009.11.019

2025 Jan
Recent Findings Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the treatment of diabetes and obesity and are increasingly being identified as promising therapies for a wide range of conditions
Since the approval of exenatide in 2005, the GLP-1 RA class has expanded to include liraglutide, semaglutide, dulaglutide, and lixisenatide, each differing in half-life, route of administration, and molecular structure (Arak et al., 2015)
